Evoke Pharma Cmn (EVOK) 1.92 $EVOK
3 Healthcare Stocks Poised to Beat Q2 Earnings
Zacks Equity Research - Zacks Investment Research - Thu Aug 11, 10:26AM CDT
in the second quarter, results have managed to outpace expectations so far.
EVOK: 1.92 (-0.05), AST: 2.79 (+0.05), ORPN: 1.62 (-0.06)
Evoke Pharma Schedules Webcast and Conference Call for Second Quarter 2016 Financial Results
GlobeNewswire - Wed Aug 10, 7:30AM CDT
Evoke Pharma, Inc. (NASDAQ:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that it will issue its financial results for the second quarter 2016 on Monday, August 15, 2016, after the close of the market.
EVOK: 1.92 (-0.05)
Evoke Pharma Completes Credit Facility Repayment
GlobeNewswire - Mon Aug 08, 7:30AM CDT
Evoke Pharma, Inc. (Nasdaq:EVOK) (the "Company"
, a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced it has paid all of the outstanding amounts of indebtedness under its loan and security agreement (the "Credit Facility" with Square 1 Bank, a division of Pacific Western Bank. With the repayment of this $4.5 million of debt, Evoke will eliminate interest expenses from the facility of approximately $250,000 a year.
EVOK: 1.92 (-0.05)
Evoke Pharma Announces $10 Million Registered Direct Offering Priced At-The-Market
GlobeNewswire - Fri Jul 29, 2:15PM CDT
Evoke Pharma, Inc. (Nasdaq:EVOK) ("Evoke Pharma" or "the Company" , today announced that it has entered into definitive agreements with institutional investors for an offering of shares of common stock with gross proceeds of approximately $10 million in a registered direct offering priced at the market price. The closing of the offering is expected to take place on or about August 3, 2016, subject to the satisfaction of customary closing conditions.
EVOK: 1.92 (-0.05)
4 Companies Demonstrate High Volume & Volatility Today Friday 7/29/2016
PR Newswire - Fri Jul 29, 10:30AM CDT
TechStockInsider.com Briefing: The small & mid-cap markets are experiencing high volume and volatility today Friday 7/29/16. Below we discuss 4 companies that demonstrate above average volume and volatility.
EVOK: 1.92 (-0.05), CLD: 4.13 (+0.04), TSRI: 6.54 (+0.26)
Four Companies To Consider for Your Portfolio in August 2016
PR Newswire - Thu Jul 28, 11:45AM CDT
TechStockInsider.com Briefing: The Fed held its two-day meeting this week and after much deliberation, the decision has been made to leave rates where they are for right now. The guidance came after identifying that the current economic state is still relatively unstable while the outlook for the global economic unrest mainly rippling from Brexit have still some uncertainty. Despite this outlook on the economy, the decision actually has spurred interest in many stocks this morning with many "bottomed out" equities seeing price reversals including:
EVOK: 1.92 (-0.05), EBIO: 4.88 (+0.15), SPU: 12.60 (+4.28)
Evoke Completes Phase 3 Clinical Trial of EVK-001 in Women with Symptoms Associated with Diabetic Gastroparesis
GlobeNewswire - Wed Jun 01, 7:30AM CDT
Evoke Pharma, Inc. (NASDAQ:EVOK), today announced that the last subject completed treatment in its pivotal Phase 3 study for EVK-001, the Company's patented nasal delivery formulation of metoclopramide for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women. The primary endpoint in the four-week, U.S. multicenter, randomized, double-blind, placebo-controlled clinical trial is the change in gastroparesis symptoms at week 4 utilizing a proprietary Patient Report Outcome (PRO) symptom assessment instrument. The Company expects to report top-line Phase 3 study results early in the third quarter of 2016.
EVOK: 1.92 (-0.05)
Evoke Pharma Presents Data from Successful Thorough ECG (TQT) Study of EVK-001 at Digestive Disease Week 2016
GlobeNewswire - Tue May 24, 7:30AM CDT
Evoke Pharma, Inc. (NASDAQ:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that data from its successful thorough electrocardiogram (ECG) study of EVK-001, its patented nasal delivery formulation of metoclopramide for the treatment of symptoms associated with acute and recurrent diabetic gastroparesis in women, were presented at Digestive Disease Week (DDW) 2016.
EVOK: 1.92 (-0.05)
Evoke Enters Exclusive Commercial Supply Agreement for Active Pharmaceutical Ingredient in EVK-001
GlobeNewswire - Thu May 19, 6:30AM CDT
Evoke Pharma, Inc. (NASDAQ:EVOK), today announced that it has signed an exclusive commercial supply agreement with COSMA S.p.A. for the active pharmaceutical ingredient (API) in its product candidate EVK-001. EVK-001 is the Company's novel nasal spray for delivery of metoclopramide for the symptomatic relief of acute and recurrent diabetic gastroparesis in women.
EVOK: 1.92 (-0.05)
Evoke Pharma Schedules Webcast and Conference Call for First Quarter 2016 Financial Results
GlobeNewswire - Thu May 05, 7:00AM CDT
Evoke Pharma, Inc. (NASDAQ:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that it will issue its financial results for the first quarter 2016 on Wednesday, May 11, 2016, after the close of the market.
EVOK: 1.92 (-0.05)
Evoke Announces Timing of Phase 3 Results from its Recently Fully Enrolled Pivotal Clinical Trial of EVK-001
GlobeNewswire - Tue May 03, 6:30AM CDT
Evoke Pharma, Inc. (NASDAQ:EVOK) today announced that it expects to provide top line data results from its pivotal Phase 3 clinical trial of EVK-001 in women with symptoms associated with diabetic gastroparesis early in the third quarter of 2016. The study was designed to enroll approximately 200 subjects and the Company has confirmed that 205 subjects have now been randomized in the trial. EVK-001 is the Company's patented nasal delivery formulation of metoclopramide for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women.
EVOK: 1.92 (-0.05)
Evoke Successfully Completes Phase 3 Clinical Trial Enrollment of EVK-001 in Women with Symptoms Associated with Diabetic Gastroparesis
GlobeNewswire - Mon Apr 25, 7:01AM CDT
Evoke Pharma, Inc. (NASDAQ:EVOK), today announced that it has successfully completed patient enrollment in its pivotal Phase 3 clinical trial of EVK-001, its patented nasal delivery formulation of metoclopramide for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women.
EVOK: 1.92 (-0.05)
What's Next for KaloBios as Shkreli Faces Fraud Charges?
Arpita Dutt - Zacks Investment Research - Fri Dec 18, 1:55PM CST
KaloBios' (KBIO) shares slumped more than 50% in pre-market trading following the arrest of CEO Martin Shkreli.
EVOK: 1.92 (-0.05), MYL: 42.36 (-0.39), AMPH: 19.00 (-0.45)
Did the Wu-Tang Clan Rat Out Martin Shkreli to SEC?
David Bartosiak - Zacks Investment Research - Thu Dec 17, 3:47PM CST
Notorious Biopharma CEO Martin Shkreli finds out the hard way that the SEC ain’t nothing to mess with.
EVOK: 1.92 (-0.05), RTRX: 16.02 (-0.15), MYL: 42.36 (-0.39), AMPH: 19.00 (-0.45)
Evoke Pharma Reports Third Quarter 2015 Results
GlobeNewswire - Thu Nov 12, 3:10PM CST
Evoke Pharma, Inc. (NASDAQ:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced its financial results for the third quarter ended September 30, 2015.
EVOK: 1.92 (-0.05)
Evoke to Participate in the Brean Capital 2015 Life Sciences Summit
GlobeNewswire - Tue Nov 10, 7:30AM CST
Evoke Pharma, Inc. (NASDAQ:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that Dave Gonyer, R.Ph., President and CEO will be participating in the Brean Capital 2015 Life Sciences Summit on Monday, November 16, 2015 at the Millennium Broadway Hotel in New York City.
EVOK: 1.92 (-0.05)
Evoke Pharma Schedules Webcast and Conference Call for Third Quarter 2015 Financial Results
GlobeNewswire - Thu Nov 05, 7:30AM CST
Evoke Pharma, Inc. (NASDAQ:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that it will issue its financial results for the third quarter of 2015 on Thursday, November 12, 2015, after the close of the market.
EVOK: 1.92 (-0.05)
Diabetic Gastroparesis - Pipeline Review, H2 2015
M2 - Fri Oct 23, 9:00AM CDT
Research and Markets (http://www.researchandmarkets.com/research/7t58rx/diabetic) has announced the addition of the "Diabetic Gastroparesis - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Diabetic Gastroparesis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Diabetic Gastroparesis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Mentioned - Cempra, Inc. - Evoke Pharma, Inc. - GlaxoSmithKline Plc - Ironwood Pharmaceuticals, Inc. - Rhythm Pharmaceuticals - Shire Plc For more information visit http://www.researchandmarkets.com/research/7t58rx/diabetic
EVOK: 1.92 (-0.05), IRWD: 13.34 (-0.08), SHPG: 187.18 (-3.04), GSK: 43.46 (+0.10), CEMP: 21.94 (+0.50)
Evoke Pharma Strengthens Financial Position
GlobeNewswire - Wed Oct 07, 7:30AM CDT
Evoke Pharma, Inc. (NASDAQ:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced the amendment of its loan and security agreement with Square 1 Bank (the "credit facility" to extend the interest-only payment term for an additional 12 months. Furthermore, through cash management and At-The-Market equity placements under its agreement with MLV & Co. LLC, Evoke had an estimated $10.7 million in cash as of September 30, 2015, an increase of $0.8 million from June 30, 2015. The Company now projects that its current cash resources should be sufficient to fund operations through October 2016.
EVOK: 1.92 (-0.05)
Evoke fulfils 75% patient enrollment in Phase 3 clinical trial under credit agreemnt
M2 - Tue Sep 29, 6:02AM CDT
Pharmaceutical company Evoke Pharma (NasdaqCM:EVOK) said on Monday that it has reached a key milestone under its USD4.5m loan, security and credit agreement with Square 1 Bank.
EVOK: 1.92 (-0.05)
3 Healthcare Stocks Poised to Beat Q2 Earnings
Zacks Equity Research - Zacks Investment Research - Thu Aug 11, 10:26AM CDT
in the second quarter, results have managed to outpace expectations so far.
EVOK: 1.92 (-0.05), AST: 2.79 (+0.05), ORPN: 1.62 (-0.06)
Evoke Pharma Schedules Webcast and Conference Call for Second Quarter 2016 Financial Results
GlobeNewswire - Wed Aug 10, 7:30AM CDT
Evoke Pharma, Inc. (NASDAQ:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that it will issue its financial results for the second quarter 2016 on Monday, August 15, 2016, after the close of the market.
EVOK: 1.92 (-0.05)
Evoke Pharma Completes Credit Facility Repayment
GlobeNewswire - Mon Aug 08, 7:30AM CDT
Evoke Pharma, Inc. (Nasdaq:EVOK) (the "Company"
, a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced it has paid all of the outstanding amounts of indebtedness under its loan and security agreement (the "Credit Facility" with Square 1 Bank, a division of Pacific Western Bank. With the repayment of this $4.5 million of debt, Evoke will eliminate interest expenses from the facility of approximately $250,000 a year. EVOK: 1.92 (-0.05)
Evoke Pharma Announces $10 Million Registered Direct Offering Priced At-The-Market
GlobeNewswire - Fri Jul 29, 2:15PM CDT
Evoke Pharma, Inc. (Nasdaq:EVOK) ("Evoke Pharma" or "the Company"
, today announced that it has entered into definitive agreements with institutional investors for an offering of shares of common stock with gross proceeds of approximately $10 million in a registered direct offering priced at the market price. The closing of the offering is expected to take place on or about August 3, 2016, subject to the satisfaction of customary closing conditions. EVOK: 1.92 (-0.05)
4 Companies Demonstrate High Volume & Volatility Today Friday 7/29/2016
PR Newswire - Fri Jul 29, 10:30AM CDT
TechStockInsider.com Briefing: The small & mid-cap markets are experiencing high volume and volatility today Friday 7/29/16. Below we discuss 4 companies that demonstrate above average volume and volatility.
EVOK: 1.92 (-0.05), CLD: 4.13 (+0.04), TSRI: 6.54 (+0.26)
Four Companies To Consider for Your Portfolio in August 2016
PR Newswire - Thu Jul 28, 11:45AM CDT
TechStockInsider.com Briefing: The Fed held its two-day meeting this week and after much deliberation, the decision has been made to leave rates where they are for right now. The guidance came after identifying that the current economic state is still relatively unstable while the outlook for the global economic unrest mainly rippling from Brexit have still some uncertainty. Despite this outlook on the economy, the decision actually has spurred interest in many stocks this morning with many "bottomed out" equities seeing price reversals including:
EVOK: 1.92 (-0.05), EBIO: 4.88 (+0.15), SPU: 12.60 (+4.28)
Evoke Completes Phase 3 Clinical Trial of EVK-001 in Women with Symptoms Associated with Diabetic Gastroparesis
GlobeNewswire - Wed Jun 01, 7:30AM CDT
Evoke Pharma, Inc. (NASDAQ:EVOK), today announced that the last subject completed treatment in its pivotal Phase 3 study for EVK-001, the Company's patented nasal delivery formulation of metoclopramide for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women. The primary endpoint in the four-week, U.S. multicenter, randomized, double-blind, placebo-controlled clinical trial is the change in gastroparesis symptoms at week 4 utilizing a proprietary Patient Report Outcome (PRO) symptom assessment instrument. The Company expects to report top-line Phase 3 study results early in the third quarter of 2016.
EVOK: 1.92 (-0.05)
Evoke Pharma Presents Data from Successful Thorough ECG (TQT) Study of EVK-001 at Digestive Disease Week 2016
GlobeNewswire - Tue May 24, 7:30AM CDT
Evoke Pharma, Inc. (NASDAQ:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that data from its successful thorough electrocardiogram (ECG) study of EVK-001, its patented nasal delivery formulation of metoclopramide for the treatment of symptoms associated with acute and recurrent diabetic gastroparesis in women, were presented at Digestive Disease Week (DDW) 2016.
EVOK: 1.92 (-0.05)
Evoke Enters Exclusive Commercial Supply Agreement for Active Pharmaceutical Ingredient in EVK-001
GlobeNewswire - Thu May 19, 6:30AM CDT
Evoke Pharma, Inc. (NASDAQ:EVOK), today announced that it has signed an exclusive commercial supply agreement with COSMA S.p.A. for the active pharmaceutical ingredient (API) in its product candidate EVK-001. EVK-001 is the Company's novel nasal spray for delivery of metoclopramide for the symptomatic relief of acute and recurrent diabetic gastroparesis in women.
EVOK: 1.92 (-0.05)
Evoke Pharma Schedules Webcast and Conference Call for First Quarter 2016 Financial Results
GlobeNewswire - Thu May 05, 7:00AM CDT
Evoke Pharma, Inc. (NASDAQ:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that it will issue its financial results for the first quarter 2016 on Wednesday, May 11, 2016, after the close of the market.
EVOK: 1.92 (-0.05)
Evoke Announces Timing of Phase 3 Results from its Recently Fully Enrolled Pivotal Clinical Trial of EVK-001
GlobeNewswire - Tue May 03, 6:30AM CDT
Evoke Pharma, Inc. (NASDAQ:EVOK) today announced that it expects to provide top line data results from its pivotal Phase 3 clinical trial of EVK-001 in women with symptoms associated with diabetic gastroparesis early in the third quarter of 2016. The study was designed to enroll approximately 200 subjects and the Company has confirmed that 205 subjects have now been randomized in the trial. EVK-001 is the Company's patented nasal delivery formulation of metoclopramide for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women.
EVOK: 1.92 (-0.05)
Evoke Successfully Completes Phase 3 Clinical Trial Enrollment of EVK-001 in Women with Symptoms Associated with Diabetic Gastroparesis
GlobeNewswire - Mon Apr 25, 7:01AM CDT
Evoke Pharma, Inc. (NASDAQ:EVOK), today announced that it has successfully completed patient enrollment in its pivotal Phase 3 clinical trial of EVK-001, its patented nasal delivery formulation of metoclopramide for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women.
EVOK: 1.92 (-0.05)
What's Next for KaloBios as Shkreli Faces Fraud Charges?
Arpita Dutt - Zacks Investment Research - Fri Dec 18, 1:55PM CST
KaloBios' (KBIO) shares slumped more than 50% in pre-market trading following the arrest of CEO Martin Shkreli.
EVOK: 1.92 (-0.05), MYL: 42.36 (-0.39), AMPH: 19.00 (-0.45)
Did the Wu-Tang Clan Rat Out Martin Shkreli to SEC?
David Bartosiak - Zacks Investment Research - Thu Dec 17, 3:47PM CST
Notorious Biopharma CEO Martin Shkreli finds out the hard way that the SEC ain’t nothing to mess with.
EVOK: 1.92 (-0.05), RTRX: 16.02 (-0.15), MYL: 42.36 (-0.39), AMPH: 19.00 (-0.45)
Evoke Pharma Reports Third Quarter 2015 Results
GlobeNewswire - Thu Nov 12, 3:10PM CST
Evoke Pharma, Inc. (NASDAQ:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced its financial results for the third quarter ended September 30, 2015.
EVOK: 1.92 (-0.05)
Evoke to Participate in the Brean Capital 2015 Life Sciences Summit
GlobeNewswire - Tue Nov 10, 7:30AM CST
Evoke Pharma, Inc. (NASDAQ:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that Dave Gonyer, R.Ph., President and CEO will be participating in the Brean Capital 2015 Life Sciences Summit on Monday, November 16, 2015 at the Millennium Broadway Hotel in New York City.
EVOK: 1.92 (-0.05)
Evoke Pharma Schedules Webcast and Conference Call for Third Quarter 2015 Financial Results
GlobeNewswire - Thu Nov 05, 7:30AM CST
Evoke Pharma, Inc. (NASDAQ:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that it will issue its financial results for the third quarter of 2015 on Thursday, November 12, 2015, after the close of the market.
EVOK: 1.92 (-0.05)
Diabetic Gastroparesis - Pipeline Review, H2 2015
M2 - Fri Oct 23, 9:00AM CDT
Research and Markets (http://www.researchandmarkets.com/research/7t58rx/diabetic) has announced the addition of the "Diabetic Gastroparesis - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Diabetic Gastroparesis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Diabetic Gastroparesis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Mentioned - Cempra, Inc. - Evoke Pharma, Inc. - GlaxoSmithKline Plc - Ironwood Pharmaceuticals, Inc. - Rhythm Pharmaceuticals - Shire Plc For more information visit http://www.researchandmarkets.com/research/7t58rx/diabetic
EVOK: 1.92 (-0.05), IRWD: 13.34 (-0.08), SHPG: 187.18 (-3.04), GSK: 43.46 (+0.10), CEMP: 21.94 (+0.50)
Evoke Pharma Strengthens Financial Position
GlobeNewswire - Wed Oct 07, 7:30AM CDT
Evoke Pharma, Inc. (NASDAQ:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced the amendment of its loan and security agreement with Square 1 Bank (the "credit facility"
to extend the interest-only payment term for an additional 12 months. Furthermore, through cash management and At-The-Market equity placements under its agreement with MLV & Co. LLC, Evoke had an estimated $10.7 million in cash as of September 30, 2015, an increase of $0.8 million from June 30, 2015. The Company now projects that its current cash resources should be sufficient to fund operations through October 2016. EVOK: 1.92 (-0.05)
Evoke fulfils 75% patient enrollment in Phase 3 clinical trial under credit agreemnt
M2 - Tue Sep 29, 6:02AM CDT
Pharmaceutical company Evoke Pharma (NasdaqCM:EVOK) said on Monday that it has reached a key milestone under its USD4.5m loan, security and credit agreement with Square 1 Bank.
EVOK: 1.92 (-0.05)
